← Scroll for more →
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Pharmaceutical Preparations
Latest Price
$0.35
Market Cap
$4.62M
TTM P/E
--
Earnings Yield
--
TTM Div Yield
--
P/B Ratio
0.14
Price at the 2026-05-13 close. Earnings yield is trailing 12-month earnings divided by price.
Price
full chart →- 1-Year Change
- -97.89%
- 52-Week High
- $23.20
- 52-Week Low
- $0.26
Daily close, 2025-05-13 to 2026-05-13
Financials
financial statements →| Quarter ending | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Last 4 quarters |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income | -$3.52M | -$8.12M | -$6.60M | -$12.44M | -$10.49M | -$9.72M | -$7.43M | -$7.86M | -$8.37M | -$6.26M | -$6.43M | -$6.05M | -$4.01M | -$3.37M | -$3.20M | -$2.45M | -$13.02M |
| Operating cash flow | -$4.00M | -$4.69M | -$7.95M | -$5.32M | -$6.18M | -$8.88M | -$11.73M | -$8.48M | -$4.24M | -$9.10M | -$8.19M | -$5.01M | -$5.59M | -$5.80M | -$3.80M | -$2.12M | -$17.30M |
Chart: net income per quarter, Sep 2022 to Jun 2026. Hover over or tap a row to chart it.
Quarters ending Sep 2024 to Jun 2026, oldest first.
Net income ($M)
Last 4 quarters -$13.02M
$0-$10M
-8.4-6.3-6.4-6.1-4.0-3.4-3.2-2.4
Operating cash flow ($M)
Last 4 quarters -$17.30M
$0-$10M
-4.2-9.1-8.2-5.0-5.6-5.8-3.8-2.1
Capital Structure
balance sheet →- Shares Outstanding
- 13.11M
- Total Debt
- --
- Long-term Debt
- --
- Long-term Debt / Capital
- --
- Cash
- $19.89M
- Current Assets
- $21.14M
- Current Liabilities
- $5.93M
Current position as of 2026-06-30.
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| EMC Capital Management | 6.7K | -- | 0.05% | -122.2K | 2026-06-30 |
Recent Material Events
all events →- Reviva Pharmaceuticals Holdings reported a net loss of $2.4 million ($0.19 per share) for the second quarter ended June 30, 2026, compared to a $6.1 million loss in the prior year period. Cash and cash equivalents increased to approximately $19.9 million as of June 30, 2026. The company filed a U.S. composition of matter patent application for a new form of brilaroxazine seeking accelerated review to extend exclusivity through 2046. FDA feedback on incorporating this formulation into the RECOVER-2 Phase 3 trial and future New Drug Application is expected in Q4 2026, with patient enrollment anticipated in the first half of 2027 subject to additional financing. Reviva Pharmaceuticals Holdings is a late-stage biopharmaceutical company developing therapies for central nervous system, inflammatory, and cardiometabolic diseases.